STOCK TITAN

Cytosorbents Corp - CTSO STOCK NEWS

Welcome to our dedicated news page for Cytosorbents (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytosorbents's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytosorbents's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.9%
Tags
none
Cytosorbents Corp

OTC:CTSO

CTSO Rankings

CTSO Stock Data

47.34M
46.68M
9.75%
39.53%
2.98%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Monmouth Junction

About CTSO

cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm"​ or "cytokine release syndrome"​ that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents'​ purification technologies are based on biocompatible, highly porous polymer beads